Nu-Med Plus (NUMD) EBIT Growth (3y) (2015 - 2025)
Nu-Med Plus (NUMD) EBIT Growth (3y) (2015 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.52 Bn | 193.92 Bn | 7.27 Bn | 3.16% |
| 2 | Stryker | 129.55 Bn | 126.07 Bn | 4.50 Bn | 19.80% |
| 3 | Medtronic | 119.60 Bn | 110.38 Bn | 6.41 Bn | 6.17% |
| 4 | Boston Scientific | 73.64 Bn | 73.10 Bn | 3.85 Bn | 31.84% |
| 5 | Edwards Lifesciences | 52.33 Bn | 48.08 Bn | 1.35 Bn | 24.88% |
| 6 | Dexcom | 34.69 Bn | 32.74 Bn | 830.00 Mn | 35.44% |
| 7 | GE HealthCare Technologies | 34.10 Bn | 31.99 Bn | 2.18 Bn | 9.04% |
| 8 | Koninklijke Philips | 26.43 Bn | 23.11 Bn | 4.55 Bn | 60.19% |
| 9 | Steris | 23.23 Bn | 22.75 Bn | 684.20 Mn | 13.06% |
| 10 | Nu-Med Plus | 2.03 Mn | 2.02 Mn | - | 0.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -15.14% |
| Sep 30, 2025 | 44.22% |
| Jun 30, 2025 | 43.60% |
| Mar 31, 2025 | 32.07% |
| Dec 31, 2024 | 56.43% |
| Sep 30, 2024 | 47.21% |
| Jun 30, 2024 | 60.07% |
| Mar 31, 2024 | 61.36% |
| Dec 31, 2023 | 52.16% |
| Sep 30, 2023 | 67.71% |
| Jun 30, 2023 | 70.56% |
| Mar 31, 2023 | 43.97% |
| Dec 31, 2022 | 69.40% |
| Sep 30, 2022 | 26.50% |
| Jun 30, 2022 | 38.01% |
| Mar 31, 2022 | 47.98% |
| Dec 31, 2021 | 30.59% |
| Sep 30, 2021 | 39.02% |
| Jun 30, 2021 | -14.31% |
| Mar 31, 2021 | -35.76% |